Table 4.
Bivariate analysis of risk factors for ulcer surgery within 30 days
| Surgery | No Surgery | p value | |
|---|---|---|---|
| Hematemesis | 53.6% | 40.3% | 0.0214 |
| Inpatient status | 35.7% | 24.5% | 0.0268 |
| Any aspirin use | 17.9% | 38.6% | 0.0001 |
| Low albumin | 74.2% | 57.1% | 0.0102 |
| Prior UGI bleeding | 53.5% | 37.3% | 0.0078 |
| Cirrhosis | 24.1% | 12.6% | 0.0223 |
| PPI treatment at admission | 46.4% | 34.2% | 0.0325 |
| Major SRH | 96.4% | 51.4% | <0.0001 |
| Endoscopic hemostatic therapy | 61.9% | 39.6% | <0.0001 |
| Successful initial hemostasis | 84.1% | 98.5% | <0.0001 |
| Any RBC, FFP and/or platelet transfusion | 96.4% | 81.5% | <0.0001 |
| CURE hemostasis prognosis score, median (IQR) | 3 (2,4) | 2 (1, 3) | <0.0001 |
| Ulcer size, Median (IQR) | 14 (7.5, 20) |
10 (7, 15) |
0.0066 |
FFP: fresh frozen plasma, HP: helicobacter pylori, NSAIDs’: non-steroidal anti- inflammatory drugs, PPI: proton pomp inhibitor, PTT: prothrombin time, RBC: red blood cell, SRH: stigmata of recent hemorrhage.